The popular form of treatment of injecting Anzemet (dolasetron mesylate) in order to overcome nausea among chemotherapy patients could lead to cardiac arrhythmias.

The FDA added the drug should be avoided especially for those cancer patients who already suffer from some form of heart disease while doctors are advised to check the electrolyte balances of all patients before starting the treatment.
“New data demonstrate that Anzemet injection can increase the risk of developing torsade de pointes, an abnormal heart rhythm, which in some cases can be fatal. Patients at particular risk are those with underlying heart conditions or those who have existing heart rate or rhythm problems”, the FDA said.
Source-Medindia